Health and correctional staff acceptability of depot buprenorphine in NSW prisons
Datos Bibliográficos
| ID | 14907142 |
|---|---|
| Autores | Sophia Little (0000-0001-7164-2623, The University of Sydney, autor de correspondencia), Bethany White (0000-0002-2049-2669, The University of Sydney), M L Moensted (0000-0002-8708-1039, The University of Sydney), Maja Moensted, Kerryn Butler (0000-0001-9173-6985), Mark Howard (0000-0002-8107-0945), M A Howard (0009-0007-5319-6923), Mark V A Howard (0000-0001-6644-9378), Jillian Roberts (0000-0002-2429-2541, Alcohol and Drug Foundation), Adrian J Dunlop (0000-0003-2394-5966, Hunter New England Local Health District) |
| Año | 2023 |
| Volumen | 114 |
| Páginas | 103978 |
| Fecha de publicación | 2023-04-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | International Journal of Drug Policy (JOURNAL) |
| Identificadores de la revista | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Editorial | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2023.103978 |
| PMID | 36870227 |
| OpenAlex | W4322762239 |
| Idioma | EN |
| Citas recibidas | 4 |
| Referencias citadas | 27 |
The introduction of depot buprenorphine into correctional settings was considered to have the potential to increase safety for patients, improve staff / patient relations and advance patient health outcomes via expanded treatment coverage and efficiencies gained through enhanced health service delivery. Support was almost universal from both correctional and health staff participating in this study. These findings build on emerging research regarding the positive impact of more flexible OAT programs and could be used to engage support for the implementation of depot buprenorphine from staff in other secure settings
Buprenorphine · Criminology · Depot · Opioid · Political science · Psychiatry · HIV, Drug Use, Sexual Risk · Law · Medicine · Nursing · Opioid Use Disorder Treatment · Psychology · Substance Abuse Treatment and Outcomes
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia
Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison
Identifying barriers and facilitators to accessing harm reduction services in prisons
Barriers to Medications for Addiction Treatment
Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails
Jail-based reentry programming to support continued treatment with medications for opioid use disorder
The paradox of control
A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System
| Obras citantes distintas | 4 |
|---|---|
| Citas por año | 4 |
| Intervalo de citas | 2025 - 2026 (2) |
| Velocidad de citación | current |
| Altamente citado | No |
| Tipos de cita | Neutras: 4 |